The product is a 48-hour opioid sparing post-surgical pain management therapy, and is a disposable, ready-to-use, single-use infusion system.
ROME and SAN FRANCISCO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- BioQ (“BioQ”) and Sophos Biotech S.r.l. (“Sophos”), both specialty pharmaceutical companies, today announced a strategic partnership agreement under which BioQ will supply and Sophos will commercialize a proprietary treatment for post-operative pain management in Italy.
The product is a 48-hour opioid sparing post-surgical pain management therapy, and is a disposable, ready-to-use, single-use infusion system, which is pre-filled at the point of manufacture with 0.2% Ropivacaine (a non-narcotic local anesthetic). The ready-to-use Ropivacaine product is a self-contained drug and administration system intended to enable delivery at the point of care, activated by a single touch and contains a unit-dose of the sterile drug.
“We are delighted to announce this new partnership with Sophos, an aggressive and nimble player in the Italian market,” said Josh Kriesel, President and CEO of BioQ Pharma. “Sophos’ experienced management team will be essential to our future success in this important European market”.
Giulio Cimini, CEO of Sophos, stated, “We are very pleased to join with BioQ to offer this important post-operative pain product to caregivers and patients in Italy”.
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company’s infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma’s commercial collaborators and strategic partners include Novartis’ Sandoz unit, Cipla, Lee’s Pharm, Lunatus, Galen Limited, Cooper Pharma, Sophos Biotech, STADA Australia, Pharma Mart, and West Pharmaceutical Services.
About Sophos Biotech
SOPHOS Biotech s.r.l. is a private Italian company managed by a team of highly skilled experts and professionals with long standing, consolidated experience in the pharmaceutical industry. Its mission is to market high quality specialty drugs and facilitate access to the best therapies available to an increasingly large number of patients, while pursuing excellence and ensuring an improved quality of life. SOPHOS Biotech owns a proprietary portfolio of specialty drugs and aims to strengthen its position through new products and new therapeutic fields of high value.
For additional information, please check the website: www.sophosbiotech.com or contact info@sophosbiotech.com.
Contact Information:
BioQ Pharma Incorporated
Josh Kriesel
BioQ Pharma
President and CEO
+1-415-336-6496
Ron Pauli
BioQ Pharma
Chief Financial Officer
+1-415-889-7707
Walter Cleymans
BioQ Pharma
Chief Commercial Officer
Phone: +32 474 (053) 253
Media:
Stephanie Carrington
Integrated Corporate Relations, Inc. (ICR)
+1-646-277-1282
Sophos Biotech s.r.l.:
Giulio Cimini
Sophos Biotech
President and CEO
+39 393 914 1828
Antonio Rocchi
Sophos Biotech
Chief Commercial Officer
+ 39 335 727 7825
